The Vascular Stent Market has witnessed significant advancements over the years, with drugeluting stents (DES) emerging as a transformative solution for patients suffering from coronary artery disease (CAD) and peripheral artery disease (PAD). These stents, designed to prevent restenosis by slowly releasing anti-proliferative drugs, have revolutionized interventional cardiology and are projected to dominate the vascular stent market in the coming years. For More Industry Insights: https://www.fairfieldmarketresearch.com/report/vascular-stentmarket
Market Growth and Forecast The global vascular stent market is poised for substantial growth, with DES accounting for over 55% of the market share in 2025. The market is projected to expand at a CAGR of 7.3% from 2025 to 2032, driven by increased incidences of cardiovascular diseases (CVDs), a rise in minimally invasive procedures, and technological advancements in stent design. The demand for DES is particularly strong in developed regions such as North America and Europe, where healthcare infrastructure and access to advanced medical devices support their widespread adoption.
Key Advantages of Drug-Eluting Stents 1. Reduction in Restenosis Rates: One of the primary advantages of DES over bare-metal stents (BMS) is their ability to significantly reduce restenosis. The controlled release of antiproliferative drugs prevents excessive tissue growth around the stent, reducing the need for repeat procedures.